| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypospadias | 7 | 2023 | 77 | 3.180 |
Why?
|
| Urinary Bladder, Neurogenic | 7 | 2023 | 60 | 3.060 |
Why?
|
| Circumcision, Male | 5 | 2022 | 26 | 2.340 |
Why?
|
| Lower Urinary Tract Symptoms | 5 | 2018 | 43 | 2.130 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2023 | 185 | 2.060 |
Why?
|
| Urinary Incontinence | 6 | 2020 | 149 | 1.890 |
Why?
|
| Ureteral Obstruction | 9 | 2023 | 143 | 1.870 |
Why?
|
| Bone Morphogenetic Protein 7 | 5 | 2015 | 63 | 1.870 |
Why?
|
| Urology | 4 | 2017 | 128 | 1.510 |
Why?
|
| Penis | 6 | 2022 | 123 | 1.460 |
Why?
|
| Nerve Block | 2 | 2022 | 176 | 1.390 |
Why?
|
| Kidney Diseases | 5 | 2016 | 691 | 1.280 |
Why?
|
| Urinary Bladder | 7 | 2018 | 575 | 1.230 |
Why?
|
| Urethral Diseases | 2 | 2020 | 36 | 1.070 |
Why?
|
| Urinary Bladder, Overactive | 2 | 2023 | 37 | 0.990 |
Why?
|
| Terminology as Topic | 3 | 2020 | 414 | 0.980 |
Why?
|
| Meningomyelocele | 3 | 2023 | 183 | 0.970 |
Why?
|
| Urination Disorders | 2 | 2014 | 61 | 0.830 |
Why?
|
| Epididymitis | 1 | 2021 | 2 | 0.830 |
Why?
|
| Orchitis | 1 | 2021 | 5 | 0.820 |
Why?
|
| Vas Deferens | 1 | 2021 | 21 | 0.810 |
Why?
|
| Disorders of Sex Development | 4 | 2020 | 88 | 0.810 |
Why?
|
| Penile Diseases | 2 | 2020 | 10 | 0.810 |
Why?
|
| Muscle, Smooth | 3 | 2010 | 236 | 0.810 |
Why?
|
| Urinary Bladder Diseases | 1 | 2021 | 45 | 0.770 |
Why?
|
| Urinary Fistula | 1 | 2020 | 27 | 0.770 |
Why?
|
| Child | 39 | 2023 | 29154 | 0.770 |
Why?
|
| Muscarinic Antagonists | 2 | 2013 | 83 | 0.760 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 46 | 0.760 |
Why?
|
| Constipation | 2 | 2020 | 177 | 0.720 |
Why?
|
| Limb Deformities, Congenital | 1 | 2020 | 112 | 0.720 |
Why?
|
| Dwarfism | 1 | 2020 | 109 | 0.720 |
Why?
|
| Pain, Postoperative | 3 | 2023 | 610 | 0.710 |
Why?
|
| Urination | 3 | 2021 | 36 | 0.700 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 126 | 0.690 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 321 | 0.690 |
Why?
|
| Postoperative Complications | 6 | 2023 | 5542 | 0.690 |
Why?
|
| Craniofacial Abnormalities | 1 | 2020 | 239 | 0.670 |
Why?
|
| Adrenergic alpha-Antagonists | 3 | 2009 | 67 | 0.670 |
Why?
|
| Wolfram Syndrome | 1 | 2018 | 1 | 0.660 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 174 | 0.640 |
Why?
|
| Pons | 1 | 2018 | 51 | 0.640 |
Why?
|
| Enterostomy | 1 | 2017 | 6 | 0.620 |
Why?
|
| Ureter | 5 | 2023 | 209 | 0.600 |
Why?
|
| Parents | 2 | 2021 | 998 | 0.590 |
Why?
|
| Pain Measurement | 1 | 2021 | 953 | 0.580 |
Why?
|
| Testis | 1 | 2020 | 717 | 0.570 |
Why?
|
| Urodynamics | 5 | 2020 | 57 | 0.550 |
Why?
|
| Adolescent | 27 | 2023 | 31252 | 0.540 |
Why?
|
| Urinary Tract | 2 | 2014 | 82 | 0.540 |
Why?
|
| Child, Preschool | 23 | 2023 | 16273 | 0.530 |
Why?
|
| Kidney Tubules, Distal | 1 | 2015 | 22 | 0.530 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2009 | 35 | 0.520 |
Why?
|
| Male | 48 | 2023 | 123000 | 0.490 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2014 | 2 | 0.490 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2015 | 142 | 0.480 |
Why?
|
| Mandelic Acids | 1 | 2013 | 3 | 0.480 |
Why?
|
| Spinal Dysraphism | 2 | 2017 | 265 | 0.460 |
Why?
|
| Kidney | 5 | 2020 | 2146 | 0.460 |
Why?
|
| Humans | 71 | 2023 | 261506 | 0.460 |
Why?
|
| Urinary Retention | 2 | 2011 | 21 | 0.450 |
Why?
|
| Vesico-Ureteral Reflux | 3 | 2023 | 81 | 0.450 |
Why?
|
| Neuromuscular Agents | 1 | 2014 | 84 | 0.450 |
Why?
|
| Infant | 15 | 2023 | 13310 | 0.440 |
Why?
|
| Incidence | 9 | 2022 | 5673 | 0.430 |
Why?
|
| Ureterocele | 2 | 2004 | 8 | 0.430 |
Why?
|
| Deamino Arginine Vasopressin | 3 | 2008 | 16 | 0.420 |
Why?
|
| Smad1 Protein | 1 | 2011 | 35 | 0.400 |
Why?
|
| Child Behavior | 1 | 2013 | 243 | 0.400 |
Why?
|
| Double-Blind Method | 4 | 2023 | 2588 | 0.390 |
Why?
|
| Midazolam | 1 | 2011 | 75 | 0.390 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1371 | 0.390 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 365 | 0.390 |
Why?
|
| Multicystic Dysplastic Kidney | 2 | 2014 | 4 | 0.390 |
Why?
|
| Societies, Medical | 2 | 2015 | 1335 | 0.390 |
Why?
|
| Anti-Anxiety Agents | 1 | 2011 | 90 | 0.380 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 1130 | 0.370 |
Why?
|
| Prospective Studies | 8 | 2022 | 12873 | 0.350 |
Why?
|
| Antidiuretic Agents | 1 | 2008 | 2 | 0.340 |
Why?
|
| Cresols | 1 | 2008 | 6 | 0.340 |
Why?
|
| Phenylpropanolamine | 1 | 2008 | 4 | 0.340 |
Why?
|
| Nocturnal Enuresis | 1 | 2008 | 2 | 0.340 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 50 | 0.330 |
Why?
|
| Cryptorchidism | 1 | 2008 | 40 | 0.330 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2008 | 830 | 0.330 |
Why?
|
| Treatment Outcome | 15 | 2023 | 32848 | 0.330 |
Why?
|
| Benzhydryl Compounds | 1 | 2008 | 85 | 0.320 |
Why?
|
| Doxazosin | 2 | 2004 | 32 | 0.310 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 401 | 0.300 |
Why?
|
| Retrospective Studies | 21 | 2023 | 37905 | 0.300 |
Why?
|
| Diverticulum | 1 | 2007 | 35 | 0.300 |
Why?
|
| Urethra | 2 | 2022 | 144 | 0.300 |
Why?
|
| Anesthesiology | 1 | 2008 | 138 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2021 | 799 | 0.270 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 62 | 0.270 |
Why?
|
| Stress, Psychological | 1 | 2013 | 1000 | 0.270 |
Why?
|
| Hydronephrosis | 3 | 2014 | 50 | 0.270 |
Why?
|
| Anxiety | 2 | 2020 | 1179 | 0.260 |
Why?
|
| Mental Disorders | 1 | 2013 | 862 | 0.260 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 2315 | 0.260 |
Why?
|
| Kidney Pelvis | 3 | 2012 | 102 | 0.250 |
Why?
|
| Kidney Transplantation | 2 | 2023 | 755 | 0.250 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.250 |
Why?
|
| Female | 33 | 2023 | 141928 | 0.250 |
Why?
|
| Caregivers | 2 | 2020 | 677 | 0.240 |
Why?
|
| Growth Substances | 1 | 2004 | 300 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2016 | 415 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 6942 | 0.230 |
Why?
|
| Urinary Reservoirs, Continent | 2 | 1999 | 31 | 0.220 |
Why?
|
| Cloaca | 2 | 2020 | 16 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 314 | 0.210 |
Why?
|
| Intestines | 2 | 2012 | 686 | 0.200 |
Why?
|
| Infant, Newborn | 11 | 2019 | 8223 | 0.200 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 1960 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2003 | 256 | 0.200 |
Why?
|
| Young Adult | 7 | 2020 | 21445 | 0.200 |
Why?
|
| Sacrococcygeal Region | 1 | 2020 | 37 | 0.190 |
Why?
|
| Fascia | 1 | 2001 | 68 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 558 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 423 | 0.190 |
Why?
|
| Ibuprofen | 1 | 2021 | 56 | 0.190 |
Why?
|
| Hydrocephalus | 1 | 2023 | 217 | 0.190 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 310 | 0.190 |
Why?
|
| Hydrocodone | 1 | 2021 | 55 | 0.190 |
Why?
|
| Puberty | 1 | 2020 | 104 | 0.190 |
Why?
|
| Blood Flow Velocity | 1 | 2022 | 475 | 0.190 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 14889 | 0.180 |
Why?
|
| Obesity | 1 | 2013 | 2884 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2022 | 189 | 0.180 |
Why?
|
| Hirschsprung Disease | 1 | 2020 | 46 | 0.180 |
Why?
|
| Urologic Surgical Procedures | 5 | 2018 | 93 | 0.180 |
Why?
|
| Cells, Cultured | 4 | 2013 | 5637 | 0.180 |
Why?
|
| Bladder Exstrophy | 1 | 1999 | 11 | 0.180 |
Why?
|
| Teratoma | 1 | 2022 | 236 | 0.180 |
Why?
|
| Acetaminophen | 1 | 2021 | 116 | 0.180 |
Why?
|
| Molecular Weight | 1 | 2020 | 629 | 0.180 |
Why?
|
| Age Factors | 6 | 2019 | 5377 | 0.180 |
Why?
|
| Sex Factors | 2 | 2018 | 2139 | 0.180 |
Why?
|
| Anesthetics | 1 | 2020 | 115 | 0.170 |
Why?
|
| Ebolavirus | 2 | 2016 | 51 | 0.170 |
Why?
|
| Urologists | 1 | 2019 | 17 | 0.170 |
Why?
|
| Urogenital System | 1 | 2019 | 59 | 0.170 |
Why?
|
| Adult | 12 | 2023 | 77950 | 0.170 |
Why?
|
| Cystadenoma, Papillary | 1 | 1998 | 5 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 5687 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2020 | 9244 | 0.170 |
Why?
|
| Quality of Life | 4 | 2022 | 4532 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 318 | 0.170 |
Why?
|
| Kidney Tubules | 2 | 2016 | 137 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2021 | 621 | 0.170 |
Why?
|
| Analgesics | 1 | 2022 | 390 | 0.170 |
Why?
|
| Pediatricians | 1 | 2019 | 58 | 0.160 |
Why?
|
| Child Health | 1 | 2019 | 54 | 0.160 |
Why?
|
| Fibrosis | 3 | 2016 | 793 | 0.160 |
Why?
|
| Enuresis | 3 | 2008 | 5 | 0.160 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2017 | 26 | 0.160 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 108 | 0.160 |
Why?
|
| Patients | 1 | 2020 | 245 | 0.150 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2017 | 45 | 0.150 |
Why?
|
| Enema | 1 | 2017 | 47 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 299 | 0.150 |
Why?
|
| Anesthesia | 1 | 2020 | 296 | 0.150 |
Why?
|
| Cytokines | 2 | 2020 | 2809 | 0.140 |
Why?
|
| Consensus | 3 | 2017 | 978 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2020 | 465 | 0.140 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 21 | 0.140 |
Why?
|
| NFATC Transcription Factors | 2 | 2014 | 96 | 0.140 |
Why?
|
| Organ Size | 1 | 2018 | 690 | 0.140 |
Why?
|
| Spinal Neoplasms | 1 | 2022 | 631 | 0.140 |
Why?
|
| Stomach | 1 | 1999 | 387 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 289 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2022 | 2803 | 0.140 |
Why?
|
| Epidemics | 1 | 2016 | 63 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2016 | 111 | 0.130 |
Why?
|
| Animals | 12 | 2020 | 59536 | 0.130 |
Why?
|
| Gastric Mucosa | 1 | 1999 | 613 | 0.130 |
Why?
|
| Ileum | 1 | 2016 | 165 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 915 | 0.130 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 134 | 0.130 |
Why?
|
| Fetal Diseases | 1 | 1998 | 388 | 0.130 |
Why?
|
| Mice | 9 | 2016 | 34495 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 1998 | 529 | 0.120 |
Why?
|
| Self Report | 1 | 2018 | 756 | 0.120 |
Why?
|
| Symptom Assessment | 1 | 2016 | 267 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 524 | 0.120 |
Why?
|
| Risk Assessment | 5 | 2019 | 6869 | 0.120 |
Why?
|
| Ureteral Neoplasms | 1 | 2016 | 228 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 99 | 0.120 |
Why?
|
| Organogenesis | 1 | 2014 | 119 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2015 | 471 | 0.120 |
Why?
|
| Neural Tube Defects | 1 | 2017 | 341 | 0.120 |
Why?
|
| Lymphangitis | 1 | 2013 | 4 | 0.120 |
Why?
|
| ADAM Proteins | 1 | 2014 | 134 | 0.120 |
Why?
|
| Spinal Cord | 1 | 2017 | 690 | 0.120 |
Why?
|
| Nephrectomy | 1 | 2018 | 779 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2020 | 1682 | 0.110 |
Why?
|
| Intestinal Mucosa | 1 | 1999 | 1081 | 0.110 |
Why?
|
| Missouri | 1 | 2013 | 49 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 7222 | 0.110 |
Why?
|
| Apoptosis | 3 | 2014 | 7591 | 0.110 |
Why?
|
| Prevalence | 1 | 2021 | 3260 | 0.110 |
Why?
|
| Reference Standards | 1 | 2014 | 339 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1945 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2019 | 2218 | 0.110 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2012 | 7 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 918 | 0.110 |
Why?
|
| Granuloma | 1 | 2013 | 154 | 0.100 |
Why?
|
| Fecal Incontinence | 1 | 2012 | 85 | 0.100 |
Why?
|
| Urography | 1 | 2011 | 43 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 589 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.100 |
Why?
|
| Adenoma | 1 | 2016 | 716 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2011 | 164 | 0.100 |
Why?
|
| Cystoscopy | 1 | 2011 | 88 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2013 | 6150 | 0.100 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 95 | 0.090 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 3154 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2016 | 899 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2015 | 1385 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2013 | 351 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 287 | 0.090 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 481 | 0.090 |
Why?
|
| Research Design | 1 | 2017 | 1544 | 0.090 |
Why?
|
| Biomechanical Phenomena | 1 | 2010 | 338 | 0.090 |
Why?
|
| Tolterodine Tartrate | 1 | 2008 | 3 | 0.090 |
Why?
|
| Phenotype | 1 | 2020 | 6295 | 0.090 |
Why?
|
| Capsules | 1 | 2008 | 53 | 0.080 |
Why?
|
| Sexual Development | 2 | 2019 | 24 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2014 | 2450 | 0.080 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2009 | 88 | 0.080 |
Why?
|
| Behavior Therapy | 1 | 2011 | 298 | 0.080 |
Why?
|
| Gene Expression | 1 | 2016 | 3570 | 0.080 |
Why?
|
| Renal Agents | 2 | 1998 | 6 | 0.080 |
Why?
|
| Disease Progression | 2 | 2017 | 6682 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 1544 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2008 | 1391 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2016 | 1225 | 0.070 |
Why?
|
| Sierra Leone | 2 | 2016 | 28 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 4314 | 0.070 |
Why?
|
| Psychometrics | 2 | 2022 | 937 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 2352 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 787 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 4113 | 0.070 |
Why?
|
| Pediatrics | 1 | 2015 | 1141 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 2203 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7702 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2016 | 11965 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 339 | 0.060 |
Why?
|
| Hospitals, Maternity | 1 | 2003 | 9 | 0.060 |
Why?
|
| Midwestern United States | 1 | 2003 | 18 | 0.060 |
Why?
|
| Collagen Type III | 1 | 2003 | 19 | 0.060 |
Why?
|
| Utilization Review | 1 | 2003 | 48 | 0.060 |
Why?
|
| HIV Infections | 1 | 2016 | 2134 | 0.060 |
Why?
|
| Guanidines | 1 | 2003 | 60 | 0.060 |
Why?
|
| Health Care Sector | 1 | 2003 | 28 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2819 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2003 | 79 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2003 | 102 | 0.060 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2023 | 40 | 0.050 |
Why?
|
| Pregnancy | 3 | 2008 | 7573 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 261 | 0.050 |
Why?
|
| Cell Division | 2 | 2004 | 2489 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 461 | 0.050 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2001 | 49 | 0.050 |
Why?
|
| Nurse Anesthetists | 1 | 2020 | 12 | 0.050 |
Why?
|
| Training Support | 1 | 2020 | 29 | 0.050 |
Why?
|
| Risk Factors | 2 | 2017 | 17523 | 0.050 |
Why?
|
| Anesthesia, Caudal | 1 | 2020 | 16 | 0.050 |
Why?
|
| Medicaid | 1 | 2003 | 279 | 0.050 |
Why?
|
| Anesthesiologists | 1 | 2020 | 49 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 4320 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 1303 | 0.050 |
Why?
|
| Pelvic Floor | 1 | 2020 | 48 | 0.050 |
Why?
|
| Operative Time | 1 | 2020 | 217 | 0.050 |
Why?
|
| Cause of Death | 1 | 2023 | 752 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 208 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 36 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2003 | 644 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8865 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2003 | 1144 | 0.040 |
Why?
|
| Ploidies | 1 | 1999 | 248 | 0.040 |
Why?
|
| Rectum | 1 | 2001 | 467 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 261 | 0.040 |
Why?
|
| Uncertainty | 1 | 2020 | 320 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 294 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 556 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 90 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2020 | 7226 | 0.040 |
Why?
|
| Hormones | 1 | 2019 | 266 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 1538 | 0.040 |
Why?
|
| Dilatation, Pathologic | 2 | 2008 | 88 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 4143 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 590 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 207 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 403 | 0.040 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2016 | 8 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2018 | 168 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 554 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 980 | 0.040 |
Why?
|
| Urine | 1 | 1997 | 143 | 0.040 |
Why?
|
| Middle Aged | 4 | 2017 | 86204 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 6009 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 295 | 0.030 |
Why?
|
| Reoperation | 1 | 2020 | 1382 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 200 | 0.030 |
Why?
|
| Malaria | 1 | 2016 | 92 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2016 | 204 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 993 | 0.030 |
Why?
|
| Recurrence | 1 | 2003 | 4758 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 292 | 0.030 |
Why?
|
| Aquaporin 2 | 1 | 2014 | 7 | 0.030 |
Why?
|
| ADAM10 Protein | 1 | 2014 | 12 | 0.030 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2014 | 27 | 0.030 |
Why?
|
| Polyuria | 1 | 2014 | 13 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 441 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 493 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 773 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 343 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 672 | 0.030 |
Why?
|
| Calcineurin | 1 | 2014 | 128 | 0.030 |
Why?
|
| Surgeons | 1 | 2020 | 519 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 625 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 608 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 497 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 649 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 627 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2012 | 46 | 0.030 |
Why?
|
| Metronidazole | 1 | 2013 | 149 | 0.030 |
Why?
|
| Diarrhea | 1 | 2016 | 686 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 1217 | 0.030 |
Why?
|
| United States | 2 | 2019 | 15433 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 995 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 430 | 0.020 |
Why?
|
| Wolffian Ducts | 1 | 2011 | 24 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 4892 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2014 | 383 | 0.020 |
Why?
|
| Cadherins | 1 | 2014 | 660 | 0.020 |
Why?
|
| Prednisone | 1 | 2013 | 984 | 0.020 |
Why?
|
| Depression | 1 | 2020 | 1715 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.020 |
Why?
|
| Lymphedema | 1 | 2013 | 239 | 0.020 |
Why?
|
| Benchmarking | 1 | 2012 | 273 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 3639 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2009 | 117 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2009 | 51 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 778 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2020 | 1375 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 242 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 1547 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 114 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1363 | 0.020 |
Why?
|
| Kidney Calices | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 671 | 0.020 |
Why?
|
| Nocturia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 311 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2009 | 198 | 0.020 |
Why?
|
| Osmolar Concentration | 2 | 1998 | 204 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 612 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Administration, Intranasal | 2 | 1998 | 190 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 2083 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 734 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 1818 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 29902 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 1085 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 650 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 1183 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 2171 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 4053 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 5047 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 1620 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.010 |
Why?
|
| Aged | 3 | 2016 | 70117 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 4917 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 4938 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 7548 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 3101 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1999 | 5767 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 181 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 6089 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2009 | 4804 | 0.010 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2001 | 43 | 0.010 |
Why?
|
| Pain | 1 | 2008 | 1658 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 1999 | 210 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 164 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 4971 | 0.010 |
Why?
|
| Endoscopy | 1 | 2001 | 479 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 3472 | 0.010 |
Why?
|
| Urinalysis | 1 | 1997 | 84 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 330 | 0.010 |
Why?
|
| Probability | 1 | 1997 | 866 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 15179 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 21713 | 0.010 |
Why?
|
| Logistic Models | 1 | 1997 | 3441 | 0.010 |
Why?
|